“…Typically, medication is the preferred treatment choice for patients with glaucoma [ 18 ]. In recent decades, several small-molecule agents, such as cholinergic agents [ 19 , 20 ], beta-adrenergic agonists [ 21 , 22 ], alpha-adrenergic agonists [ 23 ], beta-blockers [ 24 , 25 ], carbonic anhydrase inhibitors [ 26 ], prostaglandin analogs [ 27 - 29 ], and Rho-associated coiled-coil protein kinase (ROCK) inhibitors [ 30 ], have been developed and used to treat glaucoma. These molecular agents can lower IOP by reducing the rate of AH formation, increasing the outflow of AH from the unconventional outflow pathway, or decreasing the outflow resistance of AH in the conventional outflow pathway [ 23 ].…”